| Methods | D: parallel C: unclear B: double WD: 7/52 J: 1‐1‐0 DU: 3w/17w/6w | |
| Participants | N: 52/45 D: all migraine without aura C: IHS F: 91% A: 17‐48 years DU: not reported S: outpatient department of a university hospital in Brazil | |
| Interventions | P: 60 mg C1: Flunarizine 10 mg C2: Propranolol + flunarizine | |
| Outcomes | R: 15/15 vs. 14/15 vs. 14/15 (global assessment at least 'good') F: 1.3 vs. 1.2 vs. 1.1 attacks/20 days (no variance data) AU: not reported HI: 23.4 vs. 18.7 vs. 14.4 AEs: 2/15 vs. 3/15 vs. 4/15 Dropouts‐AEs: 0 vs. 0 vs. 0 (number of patients randomized to groups not fully clear) V: 0 vs. C1, (‐) vs. C2 | |
| Notes | Small groups, low propranolol dose | |
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Allocation concealment (selection bias) | Unclear risk | B ‐ Unclear |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.